Taken together, our findings provide a framework for considering a Jag1-selective blocking antibody as a therapeutic candidate in subsets of CRC patients, particularly those carrying ICN1-high/MFNG-low tumors as well as those carrying germline Apc mutations53. The gene discussed is JAG1; the disease is colorectal carcinoma.